Objective: Peroxisome proliferator-activated receptors (PPARs) are key transcription factors that regulate adipose development and function, and the conversion of white into brown-like adipocytes. Here we investigated whether PPARa and PPARg activation synergize to induce the browning of white fat. Methods: A selection of PPAR activators was tested for their ability to induce the browning of both mouse and human white adipocytes in vitro, and in vivo in lean and obese mice. Results: All dual PPARa/g activators tested robustly increased uncoupling protein 1 (Ucp1) expression in both mouse and human adipocytes in vitro, with tesaglitazar leading to the largest Ucp1 induction. Importantly, dual PPARa/g activator tesaglitazar strongly induced browning of white fat in vivo in both lean and obese male mice at thermoneutrality, greatly exceeding the increase in Ucp1 observed with the selective PPARg activator rosiglitazone. While selective PPARg activation was sufficient for the conversion of white into brown-like adipocytes in vitro, dual PPARa/ g activation was superior to selective PPARg activation at inducing white fat browning in vivo. Mechanistically, the superiority of dual PPARa/g activators is mediated at least in part via a PPARa-driven increase in fibroblast growth factor 21 (FGF21). Combined treatment with rosiglitazone and FGF21 resulted in a synergistic increase in Ucp1 mRNA levels both in vitro and in vivo. Tesaglitazar-induced browning was associated with increased energy expenditure, enhanced insulin sensitivity, reduced liver steatosis, and an overall improved metabolic profile compared to rosiglitazone and vehicle control groups. Conclusions: PPARg and PPARa synergize to induce robust browning of white fat in vivo, via PPARg activation in adipose, and PPARa-mediated increase in FGF21.
INTRODUCTION
The primary function of white adipose tissue (WAT) is to store energy for future systemic use [1] . By contrast, brown adipose tissue (BAT) consumes energy and plays a central role in thermogenesis and overall energy expenditure [2] . This unique energy-wasting capacity of BAT is due to the expression of uncoupling protein 1 (UCP1) in specialized brown adipocytes. UCP1 is expressed in the mitochondria of brown adipocytes and functions by leaking protons across the mitochondrial membrane, dissipating chemical energy in the form of heat [2] . Adult humans possess significant BAT depots which can be activated by cold or b-adrenergic receptor agonists, and BAT mass and activity inversely correlate with obesity [3e7]. Upon cold or b-adrenergic stimuli, a distinct type of thermogenic brown-like adipocytes (termed beige or brite) can also arise within WAT [8] . These adipocytes share several key characteristics with brown adipocytes, including the expression of UCP1 [9, 10] . In animal models, the browning of WAT is associated with increased energy expenditure, decreased body weight, and improved glucose tolerance [11] . Thus, increased browning of WAT has therapeutic potential for treating obesity and type 2 diabetes [12, 13] . Peroxisome proliferator-activated receptors (PPARs) are ligand-gated transcription factors. Three PPAR subtypes have been identified (a, d and g). PPARg expression is predominately restricted to adipose and is the master regulator of adipogenesis. Upon its activation by a suitable ligand, PPARg promotes differentiation of preadipocytes into adipocytes [14] . Some selective PPARg activators, including the thiazolidinediones (TZDs) such as rosiglitazone, have been shown to induce a brown fat gene transcription program in white adipocytes Original Article both in vitro [15e19] and in vivo [16,20e23] , via SIRT1-, PRDM16-, C/ EBPa-, and PGC1a-mediated mechanisms [16,24e26] . However, despite leading to an increased capacity for UCP1-mediated uncoupled respiration in adipocytes, browning induced by TZD treatment is not associated with increased energy expenditure or weight loss in vivo [21, 27] . PPARa is predominantly expressed in tissues with high oxidative capacity, such as BAT, liver, heart and kidney, where it promotes fatty acid oxidation, ketogenesis and glucose sparing [28, 29] . Selective PPARa activators, such as fibrates, can also induce the browning of WAT via PGC1a-and PRDM16-mediated mechanisms [30e33].
In the present study, we investigated whether PPARa and PPARg synergize to induce the browning of white fat. We found that selective PPARg activation is sufficient for the conversion of white adipocytes into brown-like adipocytes in vitro. However, dual PPARa/g activation is superior to selective PPARg activation at inducing browning of WAT in vivo due to a concomitant PPARa-mediated increase in fibroblast growth factor 21 (FGF21). Furthermore, in contrast to the previously reported browning of WAT induced by the selective PPARg activator rosiglitazone, the browning of WAT induced by the dual PPARa/g activator tesaglitazar is associated with increased energy expenditure, improved metabolism and decreased hepatic steatosis in diet-induced obese insulin resistant mice. Original Article 4 Figure 4 : Tesaglitazar increases energy expenditure, reduces body weight, improves metabolic control and ameliorates high fat diet-induced hepatic steatosis in obese mice. DIO male mice were used in conditions and treatments as described in Figure 3A . approved by The Regional Ethical Review Board in Gothenburg, Sweden.
MATERIALS AND METHODS

Human preadipocyte and adipocyte cultures
Human subcutaneous preadipocytes ( Figures. 1c, 5c , Figures S1, S2c, S6c and S9e) were isolated and differentiated as previously described [35] . Briefly, isolated cells were seeded and cultured in proliferation medium (Zenbio, PM-1) containing 3% FBS Gold (PAA, A15-104), 1% penicillin/streptomycin and 1 nM bFGF (Sigma, F0291). After becoming confluent (day 0), cells were differentiated in basal medium (Zenbio, BM-1) containing 3% FBS Gold (PAA, A15-104), 1% penicillin/streptomycin, 0.5 mM IBMX (Sigma, I5879), 100 nM dexamethasone (Sigma, D2915), 20 nM insulin, 1 nM T3, and 10 ng/mL BMP4 (R&D Systems, 314-BP-010/CF). After 7 days of differentiation, the medium was replaced but IBMX was omitted, and the cells were harvested on day 12 of differentiation. Freshly isolated human mature subcutaneous adipocytes were cultured as MAAC (membrane mature adipocyte aggregate cultures, Figures. 1d, 5d , Figures S1, S2d, S6d and S9f) based on a previously described method [35] . Briefly, following isolation, adipocytes were placed under a membrane and into 1 mL of A B C D E Figure 5 : PPARg alone is sufficient to convert white into brown-like adipocytes in vitro, but PPARa and PPARg have synergistic effects in vivo. (aed) qPCR analysis of Ucp1 and Cidea mRNA levels, following treatment with either vehicle, WY14643, rosiglitazone, rosiglitazone þ WY14643 or tesaglitazar (10 mM for all except rosiglitazone 1 mM) in (a) primary preadipocytes isolated from the iWAT depot of lean mice (8-day treatment during differentiation, n ¼ 3/group), (b) mouse white adipocytes (pre-differentiated from immortalized preadipocytes for 6 days followed by a 2-day treatment after differentiation, n ¼ 3/group), (c) primary human white preadipocytes (12-day treatment during differentiation, n ¼ 4e8/group) and (d) freshly isolated mature human adipocytes (7-day treatment, n ¼ 4/group). Original Article Figure 6 : Tesaglitazar induces browning of white fat in vivo, partly via FGF21. Plasma Fgf21, Fgf21 mRNA in liver and iBAT and Fabp3 and Ehhadh mRNA in liver of (a) TN and TN/RT DIO male mice (conditions and treatments as described in Figure 3A , n ¼ 4e5/group) and (b) lean male mice (conditions and treatments as described in Figure 5E ). medium (DMEM/F12) containing 10% FBS (Gibco, 10270), 1% penicillin/streptomycin and 20 nM insulin (day 0).
In vitro compound treatments
All PPAR activators were used at a final concentration of 10 mM (except rosiglitazone, used at 1 mM, or 0.01 mM, specifically in Figure 6G ) and
were obtained from AstraZeneca compound management. Recombinant mouse Fgf21 (R&D Systems, 8409-FG-025) and human Fc-FGF21 (AstraZeneca compound management) were used at a final concentration of 100 nM.
RNA isolation, cDNA synthesis, and real-time qPCR
Total RNA was extracted from adipocyte cultures using RNeasy Mini Kits (Qiagen, 74106). Adipose and liver tissue pieces were placed in a plastic tube containing a stainless-steel bead (Qiagen, 69989) and 500 mL of TRIzol, and lysed for 2 min using a tissue lyser. Following chloroform phase separation, RNA from the aqueous phase was subsequently purified using RNeasy Mini Kits (Qiagen, 74106). Isolated RNAs from cells and tissues were reverse transcribed using the High-Capacity cDNA Synthesis kit (Applied Biosystems, 4368814) and gene expression was measured using real-time PCR with Power SYBR Green master mix (Applied Biosystems) on a Quantstudio 7 Flex Real-Time PCR machine (Applied Biosystems). Tata-binding protein (TBP) was used as an internal normalization control. Primer sequences are included in Table S1. 2.6. Immunoblotting and mitochondrial DNA isolation Protein extracts were prepared from adipocytes by aspirating the medium, washing two times with PBS, and lysing the cells in RIPA buffer (50 mM Tris (pH 8.0), 150 mM NaCl, 5 mM EDTA, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS) containing protease inhibitors (Roche, 04693159001). Whole tissue pieces were placed in a plastic tube containing a stainless-steel bead (Qiagen, 69989) and RIPA buffer containing protease inhibitors (Roche, 04693159001) and lysed for 2 min using a tissue lyser. Protein content was determined using a BCA Protein Assay kit (Pierce 
RESULTS
Tesaglitazar robustly induces browning of white adipocytes in vitro
A selection of dual PPARa/g activators (aleglitazar, imiglitazar, reglitazar, chiglitazar, saroglitazar, muraglitazar, ragaglitazar and tesaglitazar), all of which reached late stage clinical development, were tested for their ability to induce browning of white adipocytes. Upon treating differentiating mouse preadipocytes for 8 days, the compounds significantly increased Ucp1 mRNA levels. Tesaglitazar, ragaglitazar and muraglitazar were identified as the strongest Ucp1 inducers, resulting in w1700-, 1600-and 1300-fold inductions, respectively ( Figure 1A ). Aleglitazar and imiglitazar both resulted in a 50-fold Ucp1 induction, whereas reglitazar, chiglitazar and saroglitazar produced w200-, 300-and 400-fold Ucp1 inductions, respectively. The adipocyte differentiation marker and PPARg responsive gene Fabp4 was increased 4-fold in all compound treated cells compared to vehicle controls, but there was no significant difference in Fabp4 levels across treatments, indicating a similar level of adipocyte differentiation ( Figure 1A) . Importantly, the browning effect of the dual PPARa/g activators was also observed in differentiating human preadipocytes. Tesaglitazar and ragaglitazar were found to be the strongest UCP1 inducers, resulting in >10-fold induction, but all dual PPARa/g activators, except imiglitazar, significantly induced UCP1 in human preadipocytes ( Figure 1C ). The dual PPARa/g activators also induced Ucp1 robustly in adipocytes: treatment of mouse adipocytes (predifferentiated for 6 days) with saroglitazar, ragaglitazar and tesaglitazar for 2 days resulted in a w80-fold increase in Ucp1 ( Figure 1B) . We have recently developed a method for long-term culture of freshly isolated mature human adipocytes [35] . Saroglitazar, ragaglitazar, and tesaglitazar treatment of freshly isolated mature human adipocytes for 7 days led to a w200-fold increase in UCP1 expression. ( Figure 1D ). To quantitatively compare the effect of the dual PPARa/g activators across the different mouse and human cell models, we generated UCP1 cDNA standard curves, allowing the determination of absolute UCP1 mRNA levels. We found that UCP1 mRNA levels were higher in tesaglitazar-treated mouse cells compared to human cells, but there was no obvious difference in UCP1 levels when comparing treatment with tesaglitazar during differentiation or of mature adipocytes directly ( Figure S1 ). It is unclear, however, if the differences in UCP1 levels between mouse and human cells reflect differences in the intrinsic capacity of these cells to brown, differences in the function of PPARg, PPARa and/or their associated cofactors, or if it merely represents differences in culture conditions. Expression of other brown fat markers such as Cidea, Cpt1b and Pdk4 were also strongly upregulated following dual PPARa/g activator treatment ( Figure S2 ). In addition to Ucp1, tesaglitazar caused significant increases in gene expression of several lipid and glucose metabolism genes and mitochondrial proteins ( Figure 1E ). Protein levels of mitochondrial proteins Atp5a, Uqcrc2, Sdhb and Ndufb8 ( Figure 1F ), and mitochondrial/nuclear DNA ratio ( Figure 1G ) were also increased, indicating increased mitochondria biogenesis. Importantly, tesaglitazar also increased Ucp1 protein levels (Figure1F). Together, these results indicate that tesaglitazar and other dual PPARa/g activators induce browning of both mouse and human white adipocytes in vitro.
Tesaglitazar robustly induces browning of white fat in vivo in lean mice
Standard housing conditions (22 C) is a cold stimulus for mice [37] , which in itself induces some degree of white fat browning. The ability of compounds to induce browning of WAT in mice was therefore assessed at mouse thermoneutrality (TN, w30 C), to better mimic standard human living thermoneutral conditions. At TN, lean mice were treated for two or five weeks with tesaglitazar and benchmarked against the known browning agent, the selective PPARg activator rosiglitazone. A two-week tesaglitazar treatment resulted in a w120fold increase in Ucp1 mRNA levels in both the inguinal WAT (iWAT) and epididymal WAT (eWAT), relative to vehicle controls. In contrast, rosiglitazone treatment had modest effects, resulting in only 3-and 6fold induction of Ucp1 in the iWAT and eWAT, respectively (Figure 2A) . The marked induction of Ucp1 in iWAT upon tesaglitazar treatment was also observed at the protein level ( Figure 2B ). Ucp1 mRNA was also increased 4-fold in the interscapular BAT (iBAT) following tesaglitazar treatment, and 2-fold following rosiglitazone treatment (Figure 2A ). Maximal induction of Ucp1 was seen after two weeks of tesaglitazar treatment, with no further increase with a five-week treatment (Figure 2A ). Pgc1a and Cidea were also robustly increased in iWAT and eWAT, and to a lesser extent in iBAT, following tesaglitazar treatment ( Figure 2C , Figure S3 ). Importantly, tesaglitazar, but not rosiglitazone treatment, was associated with increased energy expenditure (EE) (Figure 2DeE ) with no difference in locomotor activity ( Figure S3d ).
Tesaglitazar robustly induces browning of white fat in vivo in obese mice
To test whether tesaglitazar could induce the browning of WAT in obese mice and alter body weight and metabolism, diet-induced obese (DIO) mice were acclimated to TN and treated with either vehicle, rosiglitazone or tesaglitazar. Tesaglitazar was administered at three different doses, to titrate the degree of Ucp1 induction required to elicit metabolic improvements. Animals were terminated either after two weeks of treatment at TN (TN group), or after treatment for an additional two weeks while the temperature was reduced to room temperature (TN/RT group) to achieve a mild cold stimulus in order to activate Ucp1 in the newly formed beige adipocytes ( Figure 3A ). Observed plasma drug concentrations following rosiglitazone and high dose tesaglitazar treatment indicate similar average daily PPARg activation (>80%, based on an in vitro PPARg reporter gene assay), while the mid and low tesaglitazar doses resulted in w75% and w50% average daily activation, respectively ( Figure S4 ). In DIO mice at TN, tesaglitazar dose-dependently increased Ucp1 expression in iWAT, reaching a 40-fold increase at the highest tesaglitazar dose compared to vehicle controls ( Figure 3B ). Ucp1 induction was even more pronounced in the TN/RT group, with a 550-fold Ucp1 induction at the highest tesaglitazar dose, suggesting that tesaglitazar and a mild cold stimulus have synergistic effects in inducing the browning of iWAT. Tesaglitazar also robustly induced Ucp1 in eWAT, in both the TN and TN/RT groups. Rosiglitazone increased Ucp1 less than 10-fold in iWAT in TN and TN/RT groups, which was much lower than the effect of tesaglitazar. However, rosiglitazone induced Ucp1 20-to 30-fold in the eWAT of both TN and TN/RT groups, on par with the tesaglitazar effect ( Figure 3B ). In the iBAT, mid and high dose tesaglitazar increased Ucp1 1.6-fold in TN/RT mice, and by 3-fold in TN mice compared to vehicle controls, which had lower basal Ucp1 levels than TN/RT controls. Rosiglitazone, on the other hand, did not upregulate Ucp1 in the iBAT ( Figure 3B ). Pgc1a and Cidea gene expression profiles followed the same pattern as Ucp1 in the different adipose tissue depots, in both TN and TN/RT groups ( Figure 3D ). Similar expression patterns were also observed for other brown fat-enriched genes, including Elovl3 and Cox7a1, with the most pronounced effects consistently observed in the iWAT depot (Figures. S5aec) . The lowest dose of tesaglitazar had little to no effect on the expression of the brown fat markers in any adipose depots. Importantly, the large induction of Ucp1 mRNA in iWAT following mid and high dose tesaglitazar treatment was also observed at the protein level ( Figure 3C ). In summary, tesaglitazar robustly induces the recruitment of thermogenic beige adipocytes in adipose tissues of both lean and obese mice.
Tesaglitazar increases energy expenditure and reduces body weight
The tesaglitazar-induced browning in DIO mice was associated with increased EE, with the high dose tesaglitazar-treated mice displaying a 12% increased EE compared to rosiglitazone and vehicle controls at TN ( Figure 4A ). Following brown/beige adipocyte activation by subsequently reducing the temperature to RT (TN/RT group), EE almost doubled across all treatment groups (Figure 4AeB ). The temperature drop caused a further increase in EE in tesaglitazar-treated mice, with the highest dose group exhibiting a w10% higher EE compared to vehicle TN/RT controls ( Figure 4A ). Regression analysis of average EE vs. body mass shows that tesaglitazar-treated mice have significantly higher EE compared to rosiglitazone and vehicle controls, both at TN and following the temperature drop to RT ( Figure 4B ). Across treatments, there were no differences in locomotor activity ( Figure S5g) . The tesaglitazar-induced increase in EE was associated with a decrease in body weight ( Figure 4C ). Under TN conditions, body weight loss was evident only in the high dose tesaglitazar group. In contrast, rosiglitazone-treated mice displayed a non-significant increase in weight ( Figure 4C, TN group) . Following re-acclimation to RT, tesaglitazar-treated mice displayed a dose-dependent body weight loss, while vehicle-corrected weight gain in the rosiglitazone group persisted ( Figure 4C , TN/RT group), due at least in part to increased food intake ( Figure 4D ). Food intake was temporarily reduced in the high dose tesaglitazar group but returned to similar levels as vehicle control by the end of the study. The weight loss following tesaglitazar treatment was associated with a dose-dependent decrease in adipose tissue weights and adipocyte size, while rosiglitazone treated mice had increased adipose tissue weights (Figure 4EeF ). In iBAT, tesaglitazar reduced lipid content while rosiglitazone increased lipid storage (Figure 4EeF ).
Tesaglitazar improves metabolic control and ameliorates high fat diet-induced hepatic steatosis
Rosiglitazone significantly decreased fasting glucose, insulin, and increased insulin sensitivity in DIO mice (Figure 4GeI ). The metabolic benefits were more pronounced upon tesaglitazar treatment, with improvements observed in both the TN and TN/RT groups. In particular, the mid and high dose tesaglitazar groups demonstrated an almost complete normalization of fasting plasma glucose levels and a >10-fold reduction in fasting plasma insulin, compared to vehicle controls (Figure 4GeH ), resulting in a robust increase in insulin sensitivity, as indicated by the calculated quantitative insulin sensitivity check index (QUICKI, 0.44 vs. 0.25, Figure 4I ). Tesaglitazar treatment also ameliorated dyslipidemia, with a w2-fold reduction in both plasma triglycerides (TG) ( Figure 4J ) and total cholesterol levels ( Figure S5f ). Importantly, tesaglitazar treatment resulted in markedly reduced hepatic steatosis, with liver TG content reduced by more than 80% in the high dose tesaglitazar group at TN/RT compared to vehicle controls ( Figure 4K ). By contrast, rosiglitazone only modestly decreased plasma TG and cholesterol levels and did not decrease liver TG content. Plasma ketone bodies were significantly raised following tesaglitazar, but not rosiglitazone, treatment ( Figure S5e) , indicating an increased hepatic fatty acid oxidation. As assessed by an insulin tolerance test, both tesaglitazar (mid dose) and rosiglitazone treated mice displayed enhanced insulin sensitivity at TN. However, insulin sensitivity was significantly greater in tesaglitazar-treated mice compared to rosiglitazone-treated animals (Figure 4l ).
3.6. PPARg activation alone is sufficient to convert white into brown-like adipocytes in vitro, but PPARa activation and PPARg activation have synergistic effects in vivo Although tesaglitazar was superior to rosiglitazone at inducing browning in vivo, rosiglitazone and tesaglitazar were found to be equally efficacious in vitro, resulting in a 2000-to 3000-fold induction of Ucp1 and a w1000-fold increase in Cidea mRNA in primary mouse inguinal preadipocytes. Interestingly, the selective PPARa activator WY14643 had no effect on Ucp1 or Cidea gene expression ( Figure 5A ), nor did combining rosiglitazone with WY14643 in vitro further increase Ucp1 or Cidea levels compared to rosiglitazone alone ( Figure 5A) . A similar expression pattern was also observed in human preadipocytes: rosiglitazone and tesaglitazar treatment both resulted in similar induction of UCP1 mRNA (15-to 18-fold) and CIDEA mRNA (40-to 60fold), WY14643 had no significant effect on the expression of those genes, and the combination of rosiglitazone and WY14643 did not result in any further increase in UCP1 or CIDEA compared to rosiglitazone or tesaglitazar alone ( Figure 5C ). A next to identical expression pattern was observed when comparing compound effect on differentiated mouse adipocytes and freshly isolated mature human adipocytes ( Figure 5B,D) , ruling out any significant or direct contribution of PPARa activation in the browning of white fat, both in preadipocytes and adipocytes.
Treating lean mice at TN with either fenofibrate (a selective PPARa activator) or rosiglitazone (a selective PPARg activator) resulted in little to no upregulation of Ucp1 in either iWAT, eWAT, or iBAT ( Figure 5E ). However, dual PPARa/g activator treatments, given either as a combination of rosiglitazone þ fenofibrate (Rosi þ Feno), or as tesaglitazar or saroglitazar, resulted in a marked and similar increase in Ucp1 mRNA levels across iWAT and eWAT ( Figure 5E ). This indicates that a combination of PPARa and PPARg activation is necessary to promote significant browning of white fat in vivo, likely via a synergy between PPARg action in adipose tissue and PPARa action in non-adipose tissues. Metabolic characterization of lean and DIO mice treated with PPARa, PPARg and dual PPARa/g activators is provided in Supplementary Figures 7 and 8 .
Increased FGF21 contributes to dual PPARa/g activationinduced browning of WAT in vivo
Fibroblast growth factor 21 (FGF21) is a predominantly liver-derived hormone that plays an important role in lipid and glucose homeostasis [38, 39] and is regulated by PPARa [40] . FGF21 has been shown to induce browning of white fat [41, 42] . In obese mice, tesaglitazar treatment dose-dependently increased circulating Fgf21 levels (up to 8-fold at the highest dose), as well as Fgf21 expression levels in liver and iBAT (up to 3-and 6-fold, respectively). By contrast, rosiglitazone treatment did not alter Fgf21 levels ( Figure 6A ). Expression of additional PPARa target genes Fabp3 and Ehhadh [29] was also strongly increased in the livers of tesaglitazar-treated mice, indicating that tesaglitazar robustly and dose-dependently activated PPARa in the liver ( Figure 6A ). Similar increases in Fgf21, Fabp3 and Ehhadh were also observed in lean mice following treatment with either fenofibrate, tesaglitazar, saroglitazar, or the combination of rosiglitazone þ fenofibrate (Rosi þ Feno) compared to vehicle controls ( Figure 6B ). As in obese mice, lean mice treated with rosiglitazone did not display increased Fgf21 levels or increased expression of PPARa target genes in the liver ( Figure 6B ). Across all dual PPARa/g activator treatments (for example, tesaglitazar, saroglitazar and Rosi þ Feno), linear regression analysis revealed a strong correlation between circulating Fgf21 levels and Ucp1 mRNA expression in iWAT, eWAT and iBAT in both lean and obese mice. This suggests that Fgf21 plays an important role in the Ucp1 induction observed with dual PPARa/g activator treatment (Figure 6CeE ). However, even though mice treated with the selective PPARa activator fenofibrate displayed similar circulating Fgf21 levels as those achieved with the dual PPARa/g activator treatments ( Figure 6B ), Ucp1 transcript levels were not raised in this group ( Figure 5E ). This indicates that a PPARa-mediated increase in Fgf21 levels, in the absence of pharmacological PPARg activation in adipose, is not sufficient to induce browning of white fat in vivo. To test the hypothesis that FGF21 and PPARg synergize to induce browning of white fat, we treated lean mice with rosiglitazone, FGF21, rosiglitazone þ FGF21, or tesaglitazar for two weeks in thermoneutral conditions. Rosiglitazone or FGF21 monotreatments did not significantly increase expression of Ucp1. By contrast, combined FGF21 and rosiglitazone treatment increased Ucp1 mRNA levels 30fold in iWAT compared to vehicle controls, similar to the effect of tesaglitazar treatment. Similar gene expression pattern was observed for Cidea and Pdk4, and in eWAT ( Figure 6F and Figure S9a ). In vitro, combined treatment of mouse preadipocytes with Fgf21 and a low dose of rosiglitazone (inducing only a moderate Ucp1 increase) also resulted in a synergistic increase in Ucp1 mRNA levels (w1000-fold induction), superior to the effect of either rosiglitazone (w100-fold induction) or Fgf21 (w10-fold induction) alone ( Figure 6G ). Similar effects were also observed in both human preadipocytes and mature adipocytes ( Figures. S9eef) . Thus PPARg activation and Fgf21 have synergistic effects to induce browning of white fat in mice in vivo. These effects are, at least in part, cell-autonomous via direct action on white adipocytes ( Figure 6G ). Together, these results indicate that PPARg activator treatment is sufficient to promote browning of white adipocytes in vitro, with PPARa playing a negligible role. However, a combined activation of both PPARg and PPARa is needed for robust browning in vivo, via both PPARg action in adipose and an increase in Fgf21 levels from PPARa activation in the liver, and to a lesser extent iBAT. Increased browning of white fat leading to increased energy expenditure likely contributes to the whole-body improvements in metabolism observed with dual PPARa/g activator treatment.
DISCUSSION
Treatments that induce the browning of white fat and promote energy expenditure have recently been suggested as therapies for metabolic diseases [12, 13] . Current strategies to induce the formation and activation of thermogenic adipocytes typically involve mimicking a cold stimulus via b-adrenergic receptor agonism. However, this is associated with undesirable cardiovascular effects, as b-adrenergic receptors are widely expressed across multiple tissues [7] . Thus other safer approaches are needed to clinically induce the formation and activation of thermogenic fat. Given that both PPARa and PPARg have been implicated in browning [43] , we hypothesized that dual PPARa/g activators could possess a synergistic ability to induce browning of white fat. We found that dual PPARa/g activators were robust Ucp1 inducers in both human and mouse preadipocytes and mature adipocytes, with tesaglitazar affording the highest Ucp1 expression of the dual PPARa/g activators tested. In vivo, tesaglitazar treatment of both lean and obese mice robustly induced the browning of white fat, increased energy expenditure, lowered body weight, enhanced insulin sensitivity and reduced liver steatosis. The ability of some PPARg activators, including rosiglitazone, to induce Ucp1 has been well documented [16,20e23] . However, to our knowledge, the effects of dual PPARa/g activators on the browning of white fat have not previously been studied. Our results show that tesaglitazar is the most efficacious synthetic in vivo browning agent reported to date. We also show that browning of white fat via PPARa and PPARg differs between the in vitro and in vivo settings. In vitro, PPARa activation does not induce Ucp1 expression, and PPARg and dual PPARa/g activators are equally efficacious inducers of Ucp1. This indicates that selective PPARg activation is sufficient for the conversion of white into brown-like adipocytes in vitro. In vivo however, selective PPARg activation results in only moderate browning of white fat and dual PPARa/g activation (by either a single dual PPARa/g molecule or a combination of selective PPARa and PPARg activators) is necessary to induce marked browning. We propose that the superior efficacy of dual PPARa/g activators over selective PPARg activators is due their PPARa activation-mediated increase in circulating Fgf21 levels and subsequent synergistic effect with PPARg activation in adipose tissues. Indeed, tesaglitazar treatment resulted in a marked and dose-dependent increase in Fgf21 expression in both liver and iBAT and increased plasma Fgf21 levels. Plasma Fgf21 levels significantly and positively correlated with Ucp1 levels in adipose tissues in all in vivo studies performed with dual PPARa/g activation. Furthermore, combined FGF21 and rosiglitazone treatment leads to a synergistic browning of white fat in vivo, similar to the effect of tesaglitazar treatment. The liver is the main site of FGF21 production and it is transcriptionally induced in response to fasting and PPARa activation [38] and pharmacological FGF21 treatment has been shown to induce browning of white fat [41, 42] . In the present study, elevated circulating levels of Fgf21 are observed following both selective PPARa activator treatment (fenofibrate) and dual PPARa/g activator treatments (tesaglitazar, saroglitazar or the combination of rosiglitazone þ fenofibrate) but not selective PPARg activator treatment (rosiglitazone). However, PPARa activator treatment does not significantly induce browning of white fat, despite an 8-fold elevation of plasma Fgf21 levels. Similarly, in vitro treatment of preadipocytes or adipocytes with FGF21 results in little to no increase in UCP1 mRNA levels. However, a synergistic increase in UCP1 is observed when cells are treated with the combination of FGF21 and rosiglitazone, indicating that FGF21 has a direct effect on the browning of white adipocytes, however, only when PPARg is activated. An additional contribution from FGF21 is also likely to occur via the central nervous system. FGF21 can cross the bloode brain barrier and act on the paraventricular hypothalamus to increase b-adrenergic signaling in sympathetic ganglia, resulting in increased adrenergic activity in tissues such as WAT and BAT [44, 45] . In obese mice housed at TN, tesaglitazar treatment significantly decreased body weight, improved insulin sensitivity and dyslipidemia, and reduced hepatic steatosis. This is due in part to the browning of white fat, as tesaglitazar increased energy expenditure in both lean and obese mice even under thermoneutral conditions, with no difference in locomotor activity. RT is considered a mild cold challenge for mice [37] , resulting in a b-adrenergic receptor-mediated increase and activation of beige and brown adipocytes [46] . Switching the mice to RT for an additional 2 weeks after an initial 2 weeks of tesaglitazar treatment at TN (TN/RT group), resulted in an additional induction of Ucp1 in the iWAT depot, compared to tesaglitazar treated TN mice (TN group). In lean mice, maximal tesaglitazar-induced browning was observed after 2 weeks, with no additional increase in Ucp1 following 3 more weeks of treatment. Together, this suggests that tesaglitazar and a mild cold stimulus (RT) act in synergy to induce maximal browning of white fat.
Induction of thermogenic genes after treatment with the b3-adrenergic receptor agonist CL316,243 has been reported to be lessened in PPARa-null mice, indicating that PPARa plays a role in cold-induced browning [47] . Moreover, in obese mice treated with rosiglitazone (present study) at TN, reducing the temperature below TN did not result in further induction of Ucp1 expression in WAT compared to TN conditions. Notably, the relatively modest rosiglitazone-induced browning did not result in increased energy expenditure, and body weight even increased, at least in part due to increased food intake. This is consistent with previous findings showing that, in spite of an increased capacity for Ucp1-mediated uncoupled respiration [18, 19] , in vivo browning of WAT induced by treatment with selective PPARg activators is not associated with increased energy expenditure [21, 27] . Other studies have shown that selective PPARg activators attenuate the endogenous b-adrenergic stimulated activation of adipocytes in vivo [48e50]. While the tesaglitazar-mediated increase in energy expenditure is likely due to the superior browning of white fat compared to selective PPARg treatment, it could also be in part PPARa-mediated, via FGF21-dependent increased lipid and glucose metabolism and/or increased sympathetic nerve activity [45, 51] . Ucp1 was also slightly increased in iBAT following tesaglitazar treatment. While the fold increase of Ucp1 expression in iBAT is much smaller compared to that observed in iWAT (550-fold vs. 5.5-fold), it represents a large change in overall Ucp1 expression levels, given the considerably higher basal expression of Ucp1 in BAT compared to WAT [2] . Therefore the tesaglitazar-induced increase in Ucp1 expression in iBAT may also contribute to the effects of tesaglitazar on energy expenditure and metabolism. Despite identical in vitro substance concentrations across all dual PPARa/g compounds tested in the present study, the level of Ucp1 induction differed substantially between compounds with tesaglitazar being the most robust Ucp1 inducer. Comparing absolute in vitro potency values between studies is difficult since assays are designed differently. Nonetheless, one may compare the ratio between PPARg/ PPARa potency (summarized in Table S2 ). Tesaglitazar, ragaglitazar, imiglitazar, aleglitazar and muraglitazar are reported to have similar PPARa/PPARg potency ratios [52e56]. Saroglitazar on the other hand, has considerably higher selectivity towards PPARa compared to PPARg [57] , and chiglitazar and reglitazar have higher selectivity towards PPARg compared to PPARa [58, 59] . Thus neither potency nor PPARa/g selectivity appears to explain the difference in UCP1-inducing properties of the tested dual PPARa/g compounds in vitro. Selective modulation of the receptors, as opposed to activation/agonism, as measured in a reporter gene assay, may be more important to induce a brown fat gene transcription program in adipocytes [60] . PPARgmediated browning of WAT occurs via SIRT1-, PRDM16-, C/EBPa-, and PGC-1a-dependent mechanisms [16,24e26] . Post-translational modifications of PPARg also play a role in browning of white fat [27] . Thus, it is possible that tesaglitazar induces "optimal" conformational or post-translational changes at the receptor level, facilitating the interaction between key transcriptional coregulators and factors, ultimately promoting a brown fat phenotype. Tesaglitazar (GalidaÔ) was developed by AstraZeneca with the intention to treat glucose and lipid abnormalities in patients with type 2 diabetes. Although very promising anti-diabetic effects have been reported in both rodents [61] and humans [62] , the development of tesaglitazar was discontinued during phase III, because of a poor benefiterisk profile [63] . Despite the challenges of developing activators of the PPAR family of transcription factors, the present study provides clear evidence that it may be possible to develop compounds inducing the robust browning of white fat and metabolic improvements, via dual modulation of PPARa and PPARg. A combination of a safe PPARg activator together with FGF21 could also be considered as therapeutic approach for the treatment of diabetes.
CONCLUSIONS
Our study clarifies the respective roles of PPARa and PPARg in the browning of white fat in vitro and in vivo. In vitro, selective PPARg activation is sufficient for the conversion of white into brown-like adipocytes, with PPARa playing a negligible role. However, a combined activation of both PPARg and PPARa is needed for robust browning in vivo; via both PPARg action in adipose and an increase in FGF21 levels from PPARa activation in the liver, and to a lesser extent iBAT. To our knowledge, tesaglitazar is the most efficacious synthetic in vivo browning agent reported to date and is therefore a valuable new tool to study the function of beige adipocytes and the process of browning of white fat in vivo. Our study also identifies a novel opportunity to develop compounds able to robustly convert white into brown adipocytes, through the modulation of multiple PPARs. 
FUNDING AND ACKNOWLEDGEMENTS
